Compounded vs branded GLP-1: legal status after FDA shortage removal (2026)

503A vs 503B: why the distinction matters

US pharmacy compounding operates under two distinct legal pathways established by the Drug Quality and Security Act of 2013. Section 503A covers traditional patient-specific compounding by state-licensed pharmacies — a prescription is written for an individual patient, and the pharmacy compounds the dose for that patient. Section 503B covers outsourcing facilities that produce larger batches of compounded drugs without patient-specific prescriptions, primarily for hospitals and clinics.

During the 2022-2024 semaglutide and tirzepatide shortages, both 503A and 503B pharmacies expanded GLP-1 compounding. 503B facilities especially enabled the telehealth model of low-cost compounded semaglutide subscriptions, because they could produce thousands of doses at scale without individual prescriptions in advance.

When FDA declares a shortage resolved, the 503B pathway for that drug narrows significantly. 503B facilities can only compound drugs that are on FDA's official 503B bulks list. FDA proposed in April 2026 to permanently remove semaglutide and tirzepatide from that list — effectively ending bulk-scale compounded GLP-1 production from outsourcing facilities.

What changed in 2025-2026

February 2025: FDA officially declared the semaglutide shortage resolved. This started a 60-day grace period for 503B facilities to wind down compounded semaglutide production. 503A pharmacies retained narrower authority to continue patient-specific compounding under medical necessity documentation.

May 2025: FDA declared the tirzepatide shortage resolved. Same 60-day wind-down applied to tirzepatide. Several large telehealth platforms (Hims, Ro, Sequence pre-Weight Watchers acquisition) publicly transitioned subscribers off compounded tirzepatide.

April 2026: FDA published a proposed rule to permanently remove both semaglutide and tirzepatide from the 503B bulks list. The public comment period runs into mid-2026; final rule expected late 2026 or early 2027.

Mid-2026 (current status): Branded Wegovy, Ozempic, and Zepbound are widely available. Compounded GLP-1 production is permitted in narrower circumstances — 503A patient-specific compounding for documented medical necessity (allergies, dose customization) remains legal, but mass-market compounded GLP-1 subscriptions are largely shut down.

Clinical considerations: compounded is not bioequivalent

Brand Wegovy and Zepbound are FDA-approved products with documented bioequivalence, dissolution profiles, sterility assurance, and post-market adverse-event surveillance via FAERS. Compounded products are NOT FDA-approved and don't carry the same regulatory documentation. This doesn't make them inherently dangerous, but it does mean variability is higher and adverse-event tracking is fragmented.

Specific clinical risks documented in case series since 2022: dosing errors from concentration variability (some compounded products use 10 mg/mL semaglutide, others 5 mg/mL — patients used to one concentration overdosed switching to the other); contamination events from non-FDA-registered API suppliers; and inactive ingredient differences (some compounded versions use B12 or other 'enhancers' with no clinical evidence and potential allergenicity).

The compounded products that carry the lowest clinical risk are those produced by 503A pharmacies with US-sourced FDA-registered API, documented patient-specific medical necessity (typically an allergy to a brand inactive ingredient), and clear concentration labeling. If you're using a compounded GLP-1, ask your pharmacy specifically about these three quality markers.

Legal risk for patients and prescribers

Patients using compounded GLP-1s under valid prescriptions carry minimal direct legal risk. The compounding regulation governs pharmacies and prescribers, not the patient.

Prescribers face more meaningful risk. State medical boards have begun investigating prescribers who document weak medical-necessity rationale for compounded GLP-1s — particularly when prescribing in volumes that suggest mass-market compounding rather than individualized clinical decisions. The pattern that draws scrutiny: prescriber issues hundreds of identical compounded semaglutide prescriptions through a single telehealth platform, all listing 'cost' as the medical-necessity reason. 'Cost' is not a clinical reason recognized by FDA or state boards.

If you're using a compounded GLP-1 long-term, ask the prescriber what specific clinical reason is documented in your chart. 'Patient cannot afford brand' is fragile documentation. 'Patient has documented hypersensitivity to polysorbate 80' (a brand Wegovy inactive ingredient) is clinically sound documentation.

Practical decision framework

If you have insurance coverage for brand Wegovy or Zepbound at a manageable copay (<$200/month), use brand. The legal status is clean, the supply is reliable, and adverse-event surveillance is intact.

If you don't have insurance coverage but can afford NovoCare direct-pay ($499/month for Wegovy), use brand. Same reasoning — the cost differential to compounded products has narrowed substantially with NovoCare and equivalent manufacturer direct-pay options.

If you have a documented medical reason to use compounded (true allergy to brand inactive ingredients, dose customization not available in brand), 503A patient-specific compounding remains a valid path. Confirm the pharmacy's API sourcing and concentration labeling.

If your only reason for compounded GLP-1 is cost and you can't afford the brand path: this is the highest-risk scenario going into late 2026. Mass-market compounded GLP-1 supply is narrowing, and the legal status of cost-driven compounding is increasingly tenuous. Plan for transition.